Journey Medical (DERM)
(Delayed Data from NSDQ)
$3.61 USD
+0.04 (1.12%)
Updated May 14, 2024 04:00 PM ET
After-Market: $3.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
DERM 3.61 +0.04(1.12%)
Will DERM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DERM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DERM
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
DERM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?
Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B
Other News for DERM
Journey Medical GAAP EPS of -$0.53 misses by $0.30, revenue of $13M misses by $1.1M
Journey Medical Corp (DERM) (Q1 2024) Earnings Call Transcript Highlights: Navigating Growth ...
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Journey Medical Corporation (DERM) Q1 2024 Earnings Call Transcript
DERM Stock Earnings: Journey Medical Beats EPS, Misses Revenue for Q1 2024